Glecaprevir/Pibrentasvir Suppliers & Bulk Manufacturers
Available Forms: Oral tablets
Available Strengths: Glecaprevir 100 mg Pibrentasvir 40 mg
Reference Brands: Mavyret®
Category:
Hepatitis
Glecaprevir/Pibrentasvir, marketed as Mavyret®, is a fixed-dose oral antiviral used to treat chronic Hepatitis C (HCV) genotypes 1–6. Approved in the US and EU, it offers a short 8–12 week regimen for adults and children (≥3 years), with or without cirrhosis. Ideal for pharma B2B distribution.
Glecaprevir/Pibrentasvir is available in Oral tablets
and strengths such as Glecaprevir 100 mg Pibrentasvir 40 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Glecaprevir/Pibrentasvir is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Glecaprevir/Pibrentasvir can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Glecaprevir/Pibrentasvir is a fixed-dose, pan-genotypic antiviral combination used in the treatment of chronic Hepatitis C virus (HCV) infection across genotypes 1 through 6. Marketed as Mavyret® in the US and EU by AbbVie, it combines Glecaprevir, an NS3/4A protease inhibitor, and Pibrentasvir, an NS5A inhibitor, to deliver a highly effective once-daily oral regimen. Approved by the FDA and EMA, it is indicated for use in adults and pediatric patients (≥3 years), with or without cirrhosis. Glecaprevir/Pibrentasvir is widely used in pharma B2B for short-duration (typically 8–12 weeks) HCV treatment strategies across global markets.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing